Cancer Biomarkers: Can Early Detection and Monitoring of Cancer Lead to Better Outcomes?

What is it?

These are biological molecules found in blood, urine, or body tissues that are indicators of normal or abnormal processes, or of a condition or disease. Researchers are studying types of cancer biomarkers that exist at detectable levels in the blood, urine, or body tissues even before any symptoms appear. Finding and understanding these biomarkers can help researchers monitor how cancer develops and progresses, as well as help detect cancer at its earliest stages.

Uses of Cancer Biomarkers

It can be used for several purposes in cancer management and research. Some key uses of biomarkers include:

Detection

Certain biomarkers can help detect cancer before standard clinical signs or symptoms appear. For example, prostate specific antigen (PSA) testing is used along with digital rectal examination to help detect prostate cancer early. Biomarkers for other cancer types are still being researched to determine their potential for early detection.

Diagnosis

Once a possible cancer is detected, Cancer Biomarkers can help determine the type and origin of the cancer. For example, molecular profiling of tumor cells can help doctors diagnose whether a cancer is breast, lung or another type of cancer.

Prognosis

Levels of certain biomarkers in the blood or tissues may provide clues about how aggressively a cancer will grow and spread. Biomarkers can help estimate a patient's prognosis or likely outcome and guide treatment decisions. For instance, certain genetic tests of breast cancer tumors can help determine a patient's risk of recurrence.

Predict Response to Treatment

Some biomarkers can predict whether a cancer is likely to respond to a specific treatment. For example, certain biomarkers can help indicate whether a breast or lung cancer may be susceptible to certain targeted therapies. Predicting treatment response helps doctors select the most effective therapy.

Monitor Treatment Effectiveness

Cancer biomarkers may help doctors monitor how well treatment is working. Declining biomarker levels after treatment begins can serve as an early clue that the therapy is effective. Rising levels could indicate the treatment is no longer working or the cancer has returned. Biomarkers are useful for monitoring patients during and after treatment.

Identify Recurrence

Once cancer treatment ends, biomarkers may help identify cancer recurrence before other symptoms appear. Rising biomarker levels on follow-up testing could suggest the cancer has returned even when scans appear normal. This early detection of recurrence allows for prompt treatment.

Challenges

While promising, it also present some key challenges:

- Lack of validation: Many potential biomarkers still need rigorous validation studies to prove their accuracy and usefulness before clinical use. Not all early research discoveries translate into clinically useful tests.

- Sensitivity and specificity: An ideal cancer biomarker would provide very high sensitivity (ability to detect cancer when present) and specificity (ability to rule out cancer when absent). However, most biomarkers do not meet these ideal performance goals, especially in early stages.

- Complex biology: Cancers are complex diseases with biological heterogeneity between patients. Often, a single biomarker alone is not enough and panels of complementary biomarkers are needed to account for this complexity.

- Cost considerations: Developing and validating robust cancer biomarker tests requires significant research investment. Widespread clinical adoption also depends on healthcare systems ability to cover the costs.

- Limited applications: Most validated biomarkers only apply to specific cancer types or stages. Broader applications across all cancers remain a challenge and active area of research.

Despite challenges, cancer researchers remain optimistic that advancements in biomarker discovery, development and validation can help realize the promise of precision, personalized cancer care that is less invasive and more effective. Early detection through risk-stratified cancer screening using validated biomarker panels holds potential to significantly reduce cancer mortality worldwide.

Ongoing Advances in Cancer Biomarker Research

Research involving cancer biomarkers continues at a rapid pace across many areas:

Liquid Biopsy

Technologies to isolate and analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles and other biomarkers in blood are advancing rapidly. "Liquid biopsies" offer a non-invasive way to longitudinally monitor cancer dynamics and treatment response compared to repetitive tumor biopsies.

Genomic and Epigenomic Biomarkers

New technologies enable large-scale analyses of DNA, RNA, proteins and epigenetic alterations in tumors. Integrating multi-omics data holds promise to discover robust biomarker signatures for various clinical applications.

AI and Machine Learning

Computational methods involving artificial intelligence and machine learning applied to large cancer databases accelerate biomarker research. For example, these methods may help identify complex biomarker combinations with the strongest predictive power.

Clinical Validation

More cancer centers are conducting prospective clinical validation studies involving novel biomarker candidates. This helps establish robust performance characteristics and defines clinical utility before endorsement for routine patient management.

Personalized Cancer Vaccines

Research aims to discover tumor neoantigens - mutated proteins uniquely expressed in a patient's cancer cells but not healthy cells. These neoantigens show potential as protein-based cancer vaccines as well as predictive biomarkers.

Get more insights on Cancer Biomarkers